Travere Stock Analysis

TVTX -  USA Stock  

USD 15.84  0.48  3.12%

Our technical analysis module makes it possible for you to check existing technical drivers of Travere Therapeutics as well as the relationship between them. The company executives failed to add value to investors and positioning the company supply of money to exploit market volatility in May. However, diversifying your holdings with Travere Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.34. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Travere Therapeutics partners.
Additionally, take a look at World Market Map.

Search Stock Analysis 

 
Refresh
The Travere Therapeutics stock analysis report makes it easy to digest most publicly released information about Travere Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Travere stock analysis module also helps to analyze the Travere Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Travere Stock Analysis Notes

The company had not issued any dividends in recent years.

Travere Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Travere Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Travere Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Travere Therapeutics generates negative expected return over the last 90 days
Travere Therapeutics has high historical volatility and very poor performance
Latest headline from www.equities.com: Travere Therapeutics Inc gains 0.6700 percent for June 16 - Equities.com

Travere Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Travere Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Travere Therapeutics backward and forwards among themselves. Travere Therapeutics' institutional investor refers to the entity that pools money to purchase Travere Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Perceptive Advisors LlcDebt45 M474.8 M
Ra Capital Management LpCommon Shares5.6 M140.2 M
Blackrock IncCommon Shares4.8 M120.6 M
Adage Capital Partners Gp LlcCommon Shares4.5 M113.6 M
Janus Henderson Group PlcCommon Shares4.2 M103.6 M
Vanguard Group IncCommon SharesM99.9 M
Perceptive Advisors LlcCommon Shares3.3 M82.4 M
Macquarie Group LtdCommon Shares2.7 M68.4 M
Note, although Travere Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Management Efficiency

Travere Therapeutics management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 19th of June, Travere Therapeutics has the coefficient of variation of (421.94), and Risk Adjusted Performance of (0.14). Our technical analysis interface makes it possible for you to check existing technical drivers of Travere Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Travere Therapeutics, which can be compared to its competition. Please validate Travere Therapeutics coefficient of variation, maximum drawdown, skewness, as well as the relationship between the information ratio and downside variance to decide if Travere Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 15.84 per share. Given that Travere Therapeutics has jensen alpha of (0.76), we advise you to double-check Travere Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Travere Therapeutics Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Mid-point over period is an average of Travere Therapeutics highest and lowest values attained during the given period. View also all equity analysis or get more info about midpoint over period overlap studies indicator.

Travere Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Travere Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Travere Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Travere Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dube Eric M over two weeks ago via Macroaxis 
Sale by Dube Eric M of 4780 shares of Travere Therapeutics
Baynes Roy D over a month ago via Macroaxis 
Acquisition by Baynes Roy D of 9000 shares of Travere Therapeutics subject to Rule 16b-3
Aselage Steve over a month ago via Macroaxis 
Acquisition by Aselage Steve of 9000 shares of Travere Therapeutics subject to Rule 16b-3
Aselage Steve over a month ago via Macroaxis 
Exercise or conversion by Aselage Steve of 10000 shares of Travere Therapeutics subject to Rule 16b-3
Aselage Steve over three months ago via Macroaxis 
Exercise or conversion by Aselage Steve of 10000 shares of Travere Therapeutics subject to Rule 16b-3
Rote William E over three months ago via Macroaxis 
Sale by Rote William E of 1250 shares of Travere Therapeutics
Heerma Peter over three months ago via Macroaxis 
Sale by Heerma Peter of 1125 shares of Travere Therapeutics
Heerma Peter over three months ago via Macroaxis 
Acquisition by Heerma Peter of 4500 shares of Travere Therapeutics subject to Rule 16b-3
Heerma Peter over three months ago via Macroaxis 
Sale by Heerma Peter of 563 shares of Travere Therapeutics
Dube Eric M over three months ago via Macroaxis 
Acquisition by Dube Eric M of 212660 shares of Travere Therapeutics subject to Rule 16b-3
Heerma Peter over three months ago via Macroaxis 
Acquisition by Heerma Peter of 57500 shares of Travere Therapeutics subject to Rule 16b-3
Dube Eric M over three months ago via Macroaxis 
Sale by Dube Eric M of 3438 shares of Travere Therapeutics

Travere Therapeutics Predictive Daily Indicators

Travere Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Travere Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Travere Therapeutics Forecast Models

Travere Therapeutics time-series forecasting models is one of many Travere Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Travere Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Travere Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Travere Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Travere shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Travere Therapeutics. By using and applying Travere Stock analysis, traders can create a robust methodology for identifying Travere entry and exit points for their positions.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Travere Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Money Managers Now

   

Money Managers

Screen money managers from public funds and ETFs managed around the world
All  Next Launch Module
Additionally, take a look at World Market Map. Note that the Travere Therapeutics information on this page should be used as a complementary analysis to other Travere Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Travere Therapeutics Stock analysis

When running Travere Therapeutics price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
The market value of Travere Therapeutics is measured differently than its book value, which is the value of Travere that is recorded on the company's balance sheet. Investors also form their own opinion of Travere Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Travere Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Travere Therapeutics' market value can be influenced by many factors that don't directly affect Travere Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Travere Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Travere Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Travere Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.